32767-46-7

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 4,4-DIMETHYL-2-OXOCYCLOHEXANECARBOXYLATE is used as a reactant in the synthesis of pyrido[3'',2'':4,5]furo[3,2-d]pyrimidines. These compounds are studied as potent phosphodiesterase type 4 (PDE4) inhibitors, which have potential applications in the treatment of asthma and chronic obstructive pulmonary disease (COPD). METHYL 4,4-DIMETHYL-2-OXOCYCLOHEXANECARBOXYLATE's role in the synthesis process is crucial for the development of these potential therapeutic agents, highlighting its importance in the pharmaceutical industry.

Upstream product

• 186581-53-3 diazomethane 
• 2979-19-3 3,3-dimethylcyclohexanone 
• 124-38-9 carbon dioxide 
• 1193-18-6 3-methylcyclohexen-2-one 
• 17640-15-2 methyl cyanoformate 
• 4694-17-1 5,5-dimethlycyclohex-2-en-1-one 
• 616-38-6 carbonic acid dimethyl ester 

Downstream Products

• 86399-15-7 2-(2-Bromo-ethyl)-5,5-dimethyl-cyclohexanone 
• 78661-18-4 2-Methoxycarbonyl-5,5-dimethyl-2-(m-methoxyphenyl)-cyclohexanone 
• 185248-59-3 2-(Diethoxy-phosphoryloxy)-4,4-dimethyl-cyclohex-1-enecarboxylic acid methyl ester 
• 854720-02-8 4,4-cimethylcyclohex-1-ene-1-carboxylic acid 
• 32767-49-0 4,4-Dimethyl-cyclohex-1-enecarboxylic acid methyl ester 
• 32737-97-6 2c-hydroxy-4,4-dimethyl-cyclohexane-r-carboxylic acid hydrazide 
• 32737-97-6 2t-hydroxy-4,4-dimethyl-cyclohexane-r-carboxylic acid hydrazide 
• 1228780-46-8 methyl 4,4-dimethyl-2-(((trifluoromethyl)sulfonyl)oxy)cyclohex-1-ene-1-carboxylate 
• 1228780-49-1 4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carboxylic acid methyl ester 
• 1228780-51-5 (4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 
• 1228780-71-9 tert-butyl 4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazine-1-carboxylate 
• 1228780-72-0 1-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1‘-biphenyl]-2-yl)methyl)piperazine 
• 1235865-76-5 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1’-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid methyl ester 
• 1235865-77-6 [2-((1H-pyrrolo [2,3-b]pyridin-5-yl)oxy)-4-(4-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1’-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid] 

Relevant academic research and scientific papers

Synthesis, characterization and in vitro antibacterial evaluation of 1-(7,7-dimethyl-2-morpholino-5,6,7,8-tetrahydroquinazolin-4-yl)piperidine-4-carboxamide derivatives

A series of six novel 1-(7,7-dimethyl-2-morpholino-5,6,7,8-tetrahydroquinazolin-4-yl)piperidine-4-carboxamide derivatives has been synthesized and characterized using various spectral techniques (1H and 13C NMR, LCMS, IR). The antiba

Synthesis and biological activity of pyrido[3′,2′:4,5]furo[3,2- d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors

A series of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidines (PFP) were synthesized and tested for phosphodiesterase type 4 (PDE4) inhibitory activity, with the potential to treat asthma and chronic obstructive pulmonary disease (COPD). Structure-activity relation

Synthesis and antiviral study of 4-(7,7-dimethyl-4-(piperazin-1-yl)-5,6,7,8-tetrahydroquinazolin-2-yl) morpholine derivatives

Abstract: A series of 4-(7,7-dimethyl-4-(piperazin-1-yl)-5,6,7,8-tetrahydroquinazolin-2-yl)morpholine substituted sulfonamide and urea derivatives has been synthesized and characterized using spectral techniques. The antiviral activity of these compounds

Preparation method of Varonide Keebeck key intermediate

The invention discloses a preparation method of a venetoclax key intermediate, belonging to the technical field of pharmaceutical synthesis. The method comprises the steps of enabling deprotonated 3,3'-dimethylcyclohexanone to react with dimethyl carbonat

Efficient synthesis of carbon-11 labelled acylsulfonamides using [11C]CO carbonylation chemistry

Herein, a novel method for carbon-11 labeling of acyl sulfonamides by a one-step insertive [11C]CO carbonylative cross-coupling reaction between aryl halides and sulfonamides is presented. Various model compounds as well as drug molecules LY573636 (tasisulam) and ABT-199 were obtained in excellent yields. This method provides a valuable and widely applicable contribution to the continuously expanding radiochemical toolbox for PET research.

N-benzenesulfonyl benzamide compound for inhibiting Bcl-2 proteins as well as composition and application thereof

The invention relates to a compound capable of inhibiting the activity of Bcl-2 anti-apoptosis protein as well as a preparation and application thereof, in particular to an N-benzenesulfonyl benzamidecompound for inhibiting Bcl-2 proteins as shown in formula (I), or a medicine composition of a crystal form, a precursor, a pharmaceutically-acceptable salt, a three-dimensional isomer, a solvent composition or a hydrate of the N-benzenesulfonyl benzamide compound. The compound and the composition containing the compound have excellent rejection capability for Bcl-2 proteins, have better pharmacokinetics parameter characteristics, can increase the medicine concentration of the compound in animal bodies, and can improve the drug curative effect and safety. (The formula (I) is shown in the description).

Sulfonamide derivative and application thereof in pharmacy

The invention relates to a sulfonamide derivative and a pharmaceutical composition containing the same, and an application of the sulfonamide derivative and the pharmaceutical composition of the sulfonamide derivative in drug preparation, specifically the application in drug preparation of a BCL-2 family protein antagonist and the application in treatment of cancers.

Synthesis and antiviral activity of sulfonohydrazide and 1,3,4-oxadiazole derivatives of 6,6-dimethyl-9-oxo-4,5,6,7,8,9-hexahydropyrazolo[5,1-b] quinazoline

A series of new 6,6-dimethyl-9-oxo-4,5,6,7,8,9-hexahydropyrazolo[5,1-b]quinazoline substituted benzenesulfonohydrazide and 1,3,4-oxadiazole derivatives has been synthesised and characterised using spectral techniques. The antiviral activity of these compounds against an avian paramyxovirus (APMV-1) has been screened and the results show that some of the compounds possess good antiviral activity.

EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER

The present invention is directed to compounds of generic formula (I) which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatm

NEW TETRAHYDROPYRAZOLO[3,4-C]ISOQUINOLIN-5-AMINE DERIVATIVES

New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).